Skip to main content
. 2021 Oct 19;12:746492. doi: 10.3389/fimmu.2021.746492

Figure 7.

Figure 7

CXCL11 characterize the MSC niche in B-ALL. (A) CXCL11 and CXCL12 was hypoxia-tracked by using the image-iT probe and analyzed by FACS and representative CXCL11 and CXCL12 immunofluorescence staining in ALL-MSC spheroids (n = 3). (B) CXCL11 was determined by FACS in HBM-MSC and ALL-MSC spheroids (nHBM-MSC = 3, nALL-MSC = 9). (C) CXCL11 and CD19 immunostaining in BM biopsies. (D) CXCR3, CXCR4, and CXCR7 expression analyzed by FACS in B-ALL cell lines (n = 3) and primary B-ALL cells (n = 6). (E) Expression of CXCR2, CXCR3, CXCR4, and CXCR7 in B-ALL and Healthy BM CD19+CD79+ populations obtained from database GSE132509 analyses. MSC, mesenchymal stromal cell; HBM, healthy bone marrow; B-ALL, B-cell acute lymphoblastic leukemia; CAR, CXCL12-derived abundant reticular; FACS, Fluorescence-activated cell sorting. *P < 0.05; **P < 0.01; ****P < 0.0001. Error bars represent SD.